Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation.

Braaten TJ, Brahmer JR, Forde PM, Le D, Lipson EJ, Naidoo J, Schollenberger M, Zheng L, Bingham Iii CO, Shah AA, Cappelli LC.

Ann Rheum Dis. 2019 Sep 20. pii: annrheumdis-2019-216109. doi: 10.1136/annrheumdis-2019-216109. [Epub ahead of print]

PMID:
31540935
2.

Challenge of Rechallenge: When to Resume Immunotherapy Following an Immune-Related Adverse Event.

Nakajima EC, Lipson EJ, Brahmer JR.

J Clin Oncol. 2019 Oct 20;37(30):2714-2718. doi: 10.1200/JCO.19.01623. Epub 2019 Aug 28.

PMID:
31461381
3.

The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis.

Suresh K, Naidoo J, Zhong Q, Xiong Y, Mammen J, de Flores MV, Cappelli L, Balaji A, Palmer T, Forde PM, Anagnostou V, Ettinger DS, Marrone KA, Kelly RJ, Hann CL, Levy B, Feliciano JL, Lin CT, Feller-Kopman D, Lerner AD, Lee H, Shafiq M, Yarmus L, Lipson EJ, Soloski M, Brahmer JR, Danoff SK, D'Alessio F.

J Clin Invest. 2019 Jul 16;130:4305-4315. doi: 10.1172/JCI128654.

4.

Rescue therapy for patients with anti-PD-1-refractory Merkel cell carcinoma: a multicenter, retrospective case series.

LoPiccolo J, Schollenberger MD, Dakhil S, Rosner S, Ali O, Sharfman WH, Silk AW, Bhatia S, Lipson EJ.

J Immunother Cancer. 2019 Jul 8;7(1):170. doi: 10.1186/s40425-019-0661-6.

5.

Poliosis Circumscripta: A Mark of Melanoma.

Schollenberger MD, Stein JE, Taube JM, Lipson EJ.

Am J Med. 2019 Jun 23. pii: S0002-9343(19)30524-8. doi: 10.1016/j.amjmed.2019.05.042. [Epub ahead of print] No abstract available.

PMID:
31242438
6.

A Multidisciplinary Toxicity Team for Cancer Immunotherapy-Related Adverse Events.

Naidoo J, Zhang J, Lipson EJ, Forde PM, Suresh K, Moseley KF, Mehta S, Kwatra SG, Parian AM, Kim AK, Probasco JC, Rouf R, Thorne JE, Shanbhag S, Riemer J, Shah AA, Pardoll DM, Bingham CO, Brahmer JR, Cappelli LC.

J Natl Compr Canc Netw. 2019 Jun 1;17(6):712-720. doi: 10.6004/jnccn.2018.7268.

PMID:
31200355
7.

Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy.

Warner BM, Baer AN, Lipson EJ, Allen C, Hinrichs C, Rajan A, Pelayo E, Beach M, Gulley JL, Madan RA, Feliciano J, Grisius M, Long L, Powers A, Kleiner DE, Cappelli L, Alevizos I.

Oncologist. 2019 Sep;24(9):1259-1269. doi: 10.1634/theoncologist.2018-0823. Epub 2019 Apr 17.

PMID:
30996010
8.

Reply.

LoPiccolo J, Brener MI, Oshima K, Lipson EJ, Hamilton JP.

Hepatology. 2019 Jun;69(6):2718-2719. doi: 10.1002/hep.30595. No abstract available.

PMID:
30820976
9.

Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy.

Nghiem P, Bhatia S, Lipson EJ, Sharfman WH, Kudchadkar RR, Brohl AS, Friedlander PA, Daud A, Kluger HM, Reddy SA, Boulmay BC, Riker AI, Burgess MA, Hanks BA, Olencki T, Margolin K, Lundgren LM, Soni A, Ramchurren N, Church C, Park SY, Shinohara MM, Salim B, Taube JM, Bird SR, Ibrahim N, Fling SP, Homet Moreno B, Sharon E, Cheever MA, Topalian SL.

J Clin Oncol. 2019 Mar 20;37(9):693-702. doi: 10.1200/JCO.18.01896. Epub 2019 Feb 6.

PMID:
30726175
10.

Cardiovascular toxicities associated with immune checkpoint inhibitors.

Hu JR, Florido R, Lipson EJ, Naidoo J, Ardehali R, Tocchetti CG, Lyon AR, Padera RF, Johnson DB, Moslehi J.

Cardiovasc Res. 2019 Apr 15;115(5):854-868. doi: 10.1093/cvr/cvz026. Erratum in: Cardiovasc Res. 2019 Apr 15;115(5):868.

PMID:
30715219
11.

Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response.

Stein JE, Soni A, Danilova L, Cottrell TR, Gajewski TF, Hodi FS, Bhatia S, Urba WJ, Sharfman WH, Wind-Rotolo M, Edwards R, Lipson EJ, Taube JM.

Ann Oncol. 2019 Apr 1;30(4):589-596. doi: 10.1093/annonc/mdz019.

PMID:
30689736
12.

Further Lessons in Pneumocystis Pneumonia Prophylaxis-Reply.

LoPiccolo J, Mehta SA, Lipson EJ.

JAMA Intern Med. 2018 Nov 1;178(11):1566-1567. doi: 10.1001/jamainternmed.2018.5933. No abstract available.

PMID:
30398560
13.

Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series.

Moseley KF, Naidoo J, Bingham CO, Carducci MA, Forde PM, Gibney GT, Lipson EJ, Shah AA, Sharfman WH, Cappelli LC.

J Immunother Cancer. 2018 Oct 11;6(1):104. doi: 10.1186/s40425-018-0417-8.

14.

Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab.

Giraldo NA, Nguyen P, Engle EL, Kaunitz GJ, Cottrell TR, Berry S, Green B, Soni A, Cuda JD, Stein JE, Sunshine JC, Succaria F, Xu H, Ogurtsova A, Danilova L, Church CD, Miller NJ, Fling S, Lundgren L, Ramchurren N, Yearley JH, Lipson EJ, Cheever M, Anders RA, Nghiem PT, Topalian SL, Taube JM.

J Immunother Cancer. 2018 Oct 1;6(1):99. doi: 10.1186/s40425-018-0404-0.

15.

From validity to clinical utility: the influence of circulating tumor DNA on melanoma patient management in a real-world setting.

Rowe SP, Luber B, Makell M, Brothers P, Santmyer J, Schollenberger MD, Quinn H, Edelstein DL, Jones FS, Bleich KB, Sharfman WH, Lipson EJ.

Mol Oncol. 2018 Oct;12(10):1661-1672. doi: 10.1002/1878-0261.12373. Epub 2018 Sep 8.

16.

Adjuvant radiotherapy and outcomes of presumed hemorrhagic melanoma brain metastases without malignant cells.

Xia Y, Mashouf LA, Maxwell R, Peng LC, Lipson EJ, Sharfman WH, Bettegowda C, Redmond KJ, Kleinberg LR, Lim M.

Surg Neurol Int. 2018 Jul 26;9:146. doi: 10.4103/sni.sni_140_18. eCollection 2018.

17.

Nodular Regenerative Hyperplasia Associated With Immune Checkpoint Blockade.

LoPiccolo J, Brener MI, Oshima K, Lipson EJ, Hamilton JP.

Hepatology. 2018 Dec;68(6):2431-2433. doi: 10.1002/hep.30157. Epub 2018 Nov 5. No abstract available.

PMID:
30014512
18.

Corticosteroid Use and Pneumocystis Pneumonia Prophylaxis: A Teachable Moment.

LoPiccolo J, Mehta SA, Lipson EJ.

JAMA Intern Med. 2018 Aug 1;178(8):1106-1107. doi: 10.1001/jamainternmed.2018.2387. No abstract available.

PMID:
29913012
19.

Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen.

Cappelli LC, Brahmer JR, Forde PM, Le DT, Lipson EJ, Naidoo J, Zheng L, Bingham CO 3rd, Shah AA.

Semin Arthritis Rheum. 2018 Dec;48(3):553-557. doi: 10.1016/j.semarthrit.2018.02.011. Epub 2018 Mar 22.

PMID:
29573850
20.

Immunotherapy for Merkel cell carcinoma: a turning point in patient care.

Chan IS, Bhatia S, Kaufman HL, Lipson EJ.

J Immunother Cancer. 2018 Mar 23;6(1):23. doi: 10.1186/s40425-018-0335-9.

21.

State-of-the-Art Diagnosis and Treatment of Melanoma: Optimal Multidetector Computed Tomographic Practice to Identify Metastatic Disease and Review of Innovative Therapeutic Agents.

Jones BC, Lipson EJ, Childers B, Fishman EK, Johnson PT.

J Comput Assist Tomogr. 2018 May/Jun;42(3):331-339. doi: 10.1097/RCT.0000000000000697. Review.

PMID:
29287020
22.

Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade: Clinicopathologic Analysis of the Nonlichenoid Histologic Pattern.

Kaunitz GJ, Loss M, Rizvi H, Ravi S, Cuda JD, Bleich KB, Esandrio J, Sander I, Le DT, Diaz LA Jr, Brahmer JR, Drake CG, Hollmann TJ, Lacouture ME, Hellmann MD, Lipson EJ, Taube JM.

Am J Surg Pathol. 2017 Oct;41(10):1381-1389. doi: 10.1097/PAS.0000000000000900.

23.

Melanoma subtypes demonstrate distinct PD-L1 expression profiles.

Kaunitz GJ, Cottrell TR, Lilo M, Muthappan V, Esandrio J, Berry S, Xu H, Ogurtsova A, Anders RA, Fischer AH, Kraft S, Gerstenblith MR, Thompson CL, Honda K, Cuda JD, Eberhart CG, Handa JT, Lipson EJ, Taube JM.

Lab Invest. 2017 Sep;97(9):1063-1071. doi: 10.1038/labinvest.2017.64. Epub 2017 Jul 24.

24.

Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade.

Naidoo J, Cappelli LC, Forde PM, Marrone KA, Lipson EJ, Hammers HJ, Sharfman WH, Le DT, Baer AN, Shah AA, Albayda J, Manno RL, Haque U, Gutierrez AK, Bingham CO 3rd, Brahmer JR.

Oncologist. 2017 Jun;22(6):627-630. doi: 10.1634/theoncologist.2016-0390. Epub 2017 Jun 2. No abstract available.

25.

PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison.

Sunshine JC, Nguyen PL, Kaunitz GJ, Cottrell TR, Berry S, Esandrio J, Xu H, Ogurtsova A, Bleich KB, Cornish TC, Lipson EJ, Anders RA, Taube JM.

Clin Cancer Res. 2017 Aug 15;23(16):4938-4944. doi: 10.1158/1078-0432.CCR-16-1821. Epub 2017 Apr 20.

26.

Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis.

Jain A, Lipson EJ, Sharfman WH, Brant SR, Lazarev MG.

World J Gastroenterol. 2017 Mar 21;23(11):2023-2028. doi: 10.3748/wjg.v23.i11.2023.

27.

Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point 18F-FDG PET/CT Imaging in Patients with Advanced Melanoma.

Cho SY, Lipson EJ, Im HJ, Rowe SP, Gonzalez EM, Blackford A, Chirindel A, Pardoll DM, Topalian SL, Wahl RL.

J Nucl Med. 2017 Sep;58(9):1421-1428. doi: 10.2967/jnumed.116.188839. Epub 2017 Mar 30.

28.

Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade.

Lipson EJ, Lilo MT, Ogurtsova A, Esandrio J, Xu H, Brothers P, Schollenberger M, Sharfman WH, Taube JM.

J Immunother Cancer. 2017 Mar 21;5:23. doi: 10.1186/s40425-017-0228-3. eCollection 2017.

29.

Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma: Implications for Immunotherapy.

Yanik EL, Kaunitz GJ, Cottrell TR, Succaria F, McMiller TL, Ascierto ML, Esandrio J, Xu H, Ogurtsova A, Cornish T, Lipson EJ, Topalian SL, Engels EA, Taube JM.

JAMA Oncol. 2017 Jul 1;3(7):974-978. doi: 10.1001/jamaoncol.2017.0115.

30.

Transcriptional Mechanisms of Resistance to Anti-PD-1 Therapy.

Ascierto ML, Makohon-Moore A, Lipson EJ, Taube JM, McMiller TL, Berger AE, Fan J, Kaunitz GJ, Cottrell TR, Kohutek ZA, Favorov A, Makarov V, Riaz N, Chan TA, Cope L, Hruban RH, Pardoll DM, Taylor BS, Solit DB, Iacobuzio-Donahue CA, Topalian SL.

Clin Cancer Res. 2017 Jun 15;23(12):3168-3180. doi: 10.1158/1078-0432.CCR-17-0270. Epub 2017 Feb 13.

31.

Imaging and Clinical Profile Following Concurrent Stereotactic Radiation and Immune Therapy for Melanoma Brain Metastases: Preliminary Results.

Shen C, Lin DD, Redmond KJ, Link K, Kummerlowe M, Douglass J, Lipson EJ, Sharfman W, Bettegowda C, Lim M, Kleinberg LR.

Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2S):E134. doi: 10.1016/j.ijrobp.2016.06.927. No abstract available.

PMID:
27673866
32.

Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy.

Heinzerling L, Ott PA, Hodi FS, Husain AN, Tajmir-Riahi A, Tawbi H, Pauschinger M, Gajewski TF, Lipson EJ, Luke JJ.

J Immunother Cancer. 2016 Aug 16;4:50. doi: 10.1186/s40425-016-0152-y. eCollection 2016.

33.

BRAF-V600 mutational status affects recurrence patterns of melanoma brain metastasis.

Maxwell R, Garzon-Muvdi T, Lipson EJ, Sharfman WH, Bettegowda C, Redmond KJ, Kleinberg LR, Ye X, Lim M.

Int J Cancer. 2017 Jun 15;140(12):2716-2727. doi: 10.1002/ijc.30241.

34.

Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab.

Cappelli LC, Gutierrez AK, Baer AN, Albayda J, Manno RL, Haque U, Lipson EJ, Bleich KB, Shah AA, Naidoo J, Brahmer JR, Le D, Bingham CO 3rd.

Ann Rheum Dis. 2017 Jan;76(1):43-50. doi: 10.1136/annrheumdis-2016-209595. Epub 2016 Jun 15.

35.

Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors.

Cortazar FB, Marrone KA, Troxell ML, Ralto KM, Hoenig MP, Brahmer JR, Le DT, Lipson EJ, Glezerman IG, Wolchok J, Cornell LD, Feldman P, Stokes MB, Zapata SA, Hodi FS, Ott PA, Yamashita M, Leaf DE.

Kidney Int. 2016 Sep;90(3):638-47. doi: 10.1016/j.kint.2016.04.008. Epub 2016 Jun 7.

36.

Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer.

Williams TJ, Benavides DR, Patrice KA, Dalmau JO, de Ávila AL, Le DT, Lipson EJ, Probasco JC, Mowry EM.

JAMA Neurol. 2016 Aug 1;73(8):928-33. doi: 10.1001/jamaneurol.2016.1399.

PMID:
27271951
37.

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.

Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, Berry S, Chartash EK, Daud A, Fling SP, Friedlander PA, Kluger HM, Kohrt HE, Lundgren L, Margolin K, Mitchell A, Olencki T, Pardoll DM, Reddy SA, Shantha EM, Sharfman WH, Sharon E, Shemanski LR, Shinohara MM, Sunshine JC, Taube JM, Thompson JA, Townson SM, Yearley JH, Topalian SL, Cheever MA.

N Engl J Med. 2016 Jun 30;374(26):2542-52. doi: 10.1056/NEJMoa1603702. Epub 2016 Apr 19.

38.

Tumor Regression and Allograft Rejection after Administration of Anti-PD-1.

Lipson EJ, Bagnasco SM, Moore J Jr, Jang S, Patel MJ, Zachary AA, Pardoll DM, Taube JM, Drake CG.

N Engl J Med. 2016 Mar 3;374(9):896-8. doi: 10.1056/NEJMc1509268. No abstract available.

39.

Antagonists of PD-1 and PD-L1 in Cancer Treatment.

Lipson EJ, Forde PM, Hammers HJ, Emens LA, Taube JM, Topalian SL.

Semin Oncol. 2015 Aug;42(4):587-600. doi: 10.1053/j.seminoncol.2015.05.013. Epub 2015 Jun 10. Review.

40.

Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting.

Lipson EJ, Sharfman WH, Chen S, McMiller TL, Pritchard TS, Salas JT, Sartorius-Mergenthaler S, Freed I, Ravi S, Wang H, Luber B, Sproul JD, Taube JM, Pardoll DM, Topalian SL.

J Transl Med. 2015 Jul 5;13:214. doi: 10.1186/s12967-015-0572-3.

41.

Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation.

Morales RE, Shoushtari AN, Walsh MM, Grewal P, Lipson EJ, Carvajal RD.

J Immunother Cancer. 2015 Jun 16;3:22. doi: 10.1186/s40425-015-0066-0. eCollection 2015.

42.

Nivolumab: targeting PD-1 to bolster antitumor immunity.

Brahmer JR, Hammers H, Lipson EJ.

Future Oncol. 2015;11(9):1307-26. doi: 10.2217/fon.15.52. Epub 2015 Mar 23. Review.

43.

Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade.

Lipson EJ, Velculescu VE, Pritchard TS, Sausen M, Pardoll DM, Topalian SL, Diaz LA Jr.

J Immunother Cancer. 2014 Dec 16;2(1):42. doi: 10.1186/s40425-014-0042-0. eCollection 2014.

44.

Identification and management of toxicities from immune checkpoint-blocking drugs.

Teply BA, Lipson EJ.

Oncology (Williston Park). 2014 Nov;28 Suppl 3:30-8. Review.

45.

Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: a multicenter, retrospective case series.

Ravi S, Spencer K, Ruisi M, Ibrahim N, Luke JJ, Thompson JA, Shirai K, Lawson D, Bartell H, Kudchadkar R, Gunter NT, Mehnert JM, Lipson EJ.

J Immunother Cancer. 2014 Oct 14;2(1):33. doi: 10.1186/s40425-014-0033-1. eCollection 2014.

46.

Reply: Regulatory T cells-an important target for cancer immunotherapy.

Drake CG, Lipson EJ, Brahmer JR.

Nat Rev Clin Oncol. 2014 Jun;11(6):307. doi: 10.1038/nrclinonc.2013.208-c2. Epub 2014 Apr 29. No abstract available.

47.

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.

Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, Leming PD, Lipson EJ, Puzanov I, Smith DC, Taube JM, Wigginton JM, Kollia GD, Gupta A, Pardoll DM, Sosman JA, Hodi FS.

J Clin Oncol. 2014 Apr 1;32(10):1020-30. doi: 10.1200/JCO.2013.53.0105. Epub 2014 Mar 3.

48.

Detection of circulating tumor DNA in early- and late-stage human malignancies.

Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, Antonarakis ES, Azad NS, Bardelli A, Brem H, Cameron JL, Lee CC, Fecher LA, Gallia GL, Gibbs P, Le D, Giuntoli RL, Goggins M, Hogarty MD, Holdhoff M, Hong SM, Jiao Y, Juhl HH, Kim JJ, Siravegna G, Laheru DA, Lauricella C, Lim M, Lipson EJ, Marie SK, Netto GJ, Oliner KS, Olivi A, Olsson L, Riggins GJ, Sartore-Bianchi A, Schmidt K, Shih lM, Oba-Shinjo SM, Siena S, Theodorescu D, Tie J, Harkins TT, Veronese S, Wang TL, Weingart JD, Wolfgang CL, Wood LD, Xing D, Hruban RH, Wu J, Allen PJ, Schmidt CM, Choti MA, Velculescu VE, Kinzler KW, Vogelstein B, Papadopoulos N, Diaz LA Jr.

Sci Transl Med. 2014 Feb 19;6(224):224ra24. doi: 10.1126/scitranslmed.3007094.

49.

Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma.

Lipson EJ, Bodell MA, Kraus ES, Sharfman WH.

J Clin Oncol. 2014 Jul 1;32(19):e69-71. doi: 10.1200/JCO.2013.49.2314. Epub 2014 Feb 3. No abstract available.

50.

PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival.

Lipson EJ, Vincent JG, Loyo M, Kagohara LT, Luber BS, Wang H, Xu H, Nayar SK, Wang TS, Sidransky D, Anders RA, Topalian SL, Taube JM.

Cancer Immunol Res. 2013 Jul;1(1):54-63. doi: 10.1158/2326-6066.CIR-13-0034.

Supplemental Content

Loading ...
Support Center